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Introduction
After the update of the American Thyroid Association
(ATA) guidelines on diagnosis and treatment of patients
with thyroid cancer in 2015 [1], it became evident that,
for patients with low-risk thyroid cancer, these recommen-
dations presented views on the requirement for adjuvant
radioiodine therapy different from the recommendations
of the European Thyroid Association (ETA) [2] and daily
practice in Switzerland. In order to avoid offering differing
treatment options to patients and thus potential uncertain-
ties, it is important that physicians who take care of such
patients have similar views on the matter. With the inten-
tion to find a common view on the management of patients
with low-risk papillary thyroid cancer (PTC), a multidis-
ciplinary working group was initiated by the Swiss Soci-
ety for Endocrinology and Diabetes and endorsed by the
Swiss Society for Nuclear Medicine and the working group
of Swiss Endocrine Surgeons. The working group thus in-
cluded the endocrinologists, nuclear medicine physicians,
pathologists and endocrine surgeons who are authors of
this report. The discussions started with a meeting at the
Triemlispital in Zurich on 11 May 2016 and were followed
by various written exchanges of opinion during the prepa-
ration of a manuscript. The report presented herein is a
summary of the meeting and the post-meeting discussions.
The care of patients with thyroid cancer is a wide area
that covers presurgical management of thyroid nodules,
the choice of the appropriate surgery and postsurgical care
including radioiodine treatment. Our discussions focused
primarily on the identification of patients with low-risk
PTC and their initial treatment options.
Obtaining high-level evidence on patients with low-risk
PTC is difficult because the disease progresses very slowly
and controlled long-term studies lasting many years in
thousands of patients are needed in order to acquire the
necessary data. These trials are very difficult to perform. It
is, therefore, not surprising that a substantial part of the ev-
idence is based on retrospective and/or observational data.
The need for long-term intervention and the actual quality
of the data result in different opinions/strategies of the var-
ious involved stakeholders, which are also summarised in
this article.
Endocrine perspective
The incidence of differentiated thyroid cancer (DTC) has
increased in the past 20 years, which is primarily the result
of the more frequent use of ultrasound imaging in the man-
agement of thyroid disorders. The higher prevalence is al-
most entirely due to the discovery of small PTCs of less
than 2 cm. This observation had already been reported 10
years ago in the USA [3]. The most convincing association
between increased use of thyroid ultrasound and increased
incidence of small PTCs was reported recently from South
Korea [4]. Here, the addition of routine thyroid ultrasound
in patients who were screened primarily for other malig-
nancies such as breast cancer led to a more than ten-fold
increase in thyroid cancer incidence that was almost en-
tirely due to the accidental discovery of small PTCs [4].
Correspondence:
Henryk Zulewski, MD,
Stadtspital Triemli, Birmes-
ndorferstrasse 489,
CH-8063 Zürich, hen-
ryk.zulewski[at]triem-
li.zuerich.ch
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 1 of 6
In Switzerland also, the incidence of thyroid cancer in-
creased, although to lesser extent than in the USA, Italy or
South Korea [5, 6].
For many years, patients with low-risk DTC were treated
with total thyroidectomy, radioiodine treatment and thy-
roid stimulating hormone-suppressive thyroxine therapy.
Various observational studies examined the impact of ad-
juvant radioiodine therapy in low-risk patients and found
no convincing benefit [7–11]. Indeed, the disease-specific
survival was excellent and similar with and without ra-
dioiodine treatment in these studies, with 99% disease-spe-
cific survival after 20 years [6]. Similarly, the tumour re-
currence rate was comparable and was estimated to be 1
to 4% after 7 to 20 years of follow-up [11–13]. Although
these were retrospective observational studies and different
risk scores were used to define low-risk, their results were
quite consistent. Concerns were raised regarding the long-
term safety of radioiodine treatment in patients with low-
risk DTC, and everybody can agree that unnecessary expo-
sure to radiation should be avoided.
The increased incidence of mainly low-risk DTC, the lack
of evidence for the therapeutic benefit of total thyroidecto-
my and of radioiodine therapy in these patients [7–11], as
well as the safety concerns mentioned above thus prompt-
ed a reassessment of the management of patients with low-
risk PTC.
This led to the new comprehensive recommendations re-
leased by the ATA in 2015 [1]. The definition of low-risk
thyroid cancer according to the new ATA guidelines is giv-
en in table 1. As compared with previous guidelines (of the
ATA and ETA), the new guidelines additionally describe
the risk of structural disease recurrence in patients with-
out structurally identifiable disease after initial therapy as a
continuum based on various features including the number
of microscopic lymph node metastases, vascular invasion
and biological features of the tumour, but without defining
a size limit for the primary PTC (fig.1).
Surgeons’ perspective
In view of the relatively low aggressiveness of differentiat-
ed PTC with excellent prognosis, surgical procedures may
have to be weighed against the risk for surgical complica-
tions. The invasiveness of the thyroid surgery should thus
match the presumed aggressiveness of the tumour.
Numerous studies have shown that in patients with isolated
PTC, less invasive surgical procedures such as lobectomy
had similar outcomes as total thyroidectomy regarding sur-
vival, but with significantly reduced complication rates,
namely, reduced frequency of recurrent nerve palsy and re-
duced rate of permanent hypoparathyroidism [14–16].
The risk for local and distant metastases increases with in-
creasing size of the PTC, especially if the tumour size ex-
Figure 1: Description of the risk for structural disease recurrence as a continuum in differentiated thyroid cancer (adapted from [1]) in patients
without structurally identifiable disease after first initial therapy.
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Table 1: Characteristics of a low-risk thyroid cancer according to the
new ATA 2015 guidelines (adapted from [1]).
Papillary thyroid
cancer with all of
the following:
All macroscopic tumour has been resected
Absence of local of distant metastases
Without tumour invasion of loco-regional tis-
sues
No aggressive feature on histology (e.g., tall
cell, hobnail variant, columnar cell carcinoma
If 131I is given, no evidence for radioiodine-avid
foci outside the thyroid bed on first post-treat-
ment whole-body radioiodine scan
No vascular invasion
No clinical evidence for lymph node metastases
or LN1 with up to five micrometastases (<0.2
cm in largest dimension)
Intrathyroidal, encapsulated follicular variant of PTC
Intrathyroidal, well differentiated follicular thyroid cancer with capsu-
lar invasion and no or minimal (<4 foci) vascular invasion
Intrathyroidal, papillary microcarcinoma, unifocal or multifocal, includ-
ing BRAF mutation
ceeds 2 cm, as has been described in an observational study
involving 366 patients with PTC [17]. This is the reason
why it was decided at the thyroid cancer board meeting to
limit the low-risk definition to a size of 2 cm or less, in
contrast to the ATA guidelines where no formal size limit
was set in the definition of low risk. The ATA guidelines
also included in their risk assessment for PTC microscopic
lymph node involvement and one could argue that without
collection of lymph nodes use of such a criterion for proper
risk estimation of PTC would be impossible.
In contrast to the ATA guidelines, we decided to limit the
low-risk definition to the size of 20 mm. With a PTC of
20 mm or less, the risk for clinically relevant lymph node
involvement is very low [17]. It is for this reason that
we also do not recommend routine ipsilateral prophylactic
clearance of lymph nodes. This recommendation does not,
however, exclude exceptional cases such as familial forms
of PTC or postradiation PTC, where a different approach,
including total thyroidectomy and/or prophylactic clear-
ance of lymph nodes, could be justified. Given the high-
er risk of complications, such procedures should be limited
to very experienced surgeons [18–22]. However, as there
are no proven benefits concerning long-term outcome [21,
23–25] and most thyroid procedures in Switzerland are not
performed by subspecialised surgeons, prophylactic lymph
node dissection cannot be recommended as a standard pro-
cedure in patients with small a PTC without macroscopic
evidence of lymph node metastases.
The planning of the initial thyroid procedure should there-
fore be risk oriented, based on the available preoperative
data, especially ultrasound studies to detect potential
macroscopic lymph node metastases. In the absence of
macroscopic lymph node metastases and the presence of a
uninodular PTC of 20 mm or less, a lobectomy could be
sufficient and should be discussed with patient.
Nuclear medicine perspective
For a long time, routine radioiodine ablation was an es-
tablished standard of care in differentiated thyroid cancer
(DTC) patients, an exception being the PTC microcarcino-
ma (less than 10 mm. In these cases, there is an overall
agreement to refrain from radioiodine treatment if total
thyroidectomy was performed, and from completion
surgery if lobectomy was the initial treatment and the diag-
nosis of the microcarcinoma an incidental finding.
According to the new ATA guidelines, radioiodine ablation
on a routine basis in low-risk DTC patients is not rec-
ommended. This recommendation, however, was made in
spite of the presence of conflicting observational data. In
absence of 131I administration, the adjuvant and a fortiori
therapeutic goals of radioiodine will be lost in patients with
unsuspected persistent metastatic disease foci after surgery.
Only 2 out of 101 ATA 2015 recommendations were sup-
ported by a high level of evidence and the ATA guidelines
were challenged by many other scientific societies owing
to the observational character of the studies that were the
basis for this recommendation and because such an ap-
proach had not been tested in prospective studies.
For example, a reduction of recurrences and better out-
come are expected in patients with low-risk PTCs larger
than 20 mm when radioiodine ablation is part of their treat-
ment, and these differences are relevant for clinical deci-
sion making. Indeed, low-risk radioiodine ablated DTC pa-
tients with an excellent response can be safely considered
cured. A minimal follow-up (clinical examination and thy-
roglobulin measurement) should be arranged every 1 to 2
years for such patients, thus increasing their comfort and
saving resources.
On the other hand, the occurrence of non-thyroidal primary
malignancies and the potential association with radioio-
dine treatment are important concerns in patients with
DTC.
An increased incidence of second cancer has been reported
after radioiodine treatment for thyroid cancer, but data
were conflicting and a causal relationship may be difficult
to establish [23–25]. An increased risk of second malig-
nancies is definitely proved when cumulative exposures
exceed 37 GBq (1000 mCi). It should be noted, however,
that these levels are reached only in patients with advanced
disease and a high risk of disease-related death. Addition-
ally, the absolute risk for single patients remains low even
in these cases, with standardised incidence ratios about 1.3
to 1.5 [26]. Notably, significantly lower activities (0.8–3.7
GBq [20–100 mCi]) are currently employed to ablate DTC
in low-risk patients and recent studies concluded that the
risk of a second primary malignancy is not increased in pa-
tients receiving these levels of radioiodine compared with
those who did not receive radioiodine [27].
Notwithstanding, the risks and benefits of any treatment
must be weighted and administration of radioiodine must
be justified and optimised according to the ALARA (as
low as reasonably achievable) concept. This a specific task
of nuclear medicine physicians, as stated in national and
international regulations.
In conclusion, since the literature cannot provide a basis
for advice for or against current guidelines, further long-
term follow-up studies are needed before recommenda-
tions to change effective clinical practice are accepted as
standard of care.
Prospective randomised trials in Europe (ESTIMABL2,
IoN) and South Korea (Clinical trial.gov identifier
NCT01837745, NCT01398085, and NCT02418247) to as-
sess the potential benefit of radioiodine ablation in low-
risk patients are underway and first results will be available
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Table 2: Proposed standardised reporting for differentiated thyroid
cancer.
Diagnosis according to the TNM system (e.g., pT2,pNx, L1, V0, R0)
Histological type: e.g., classical papillary thyroid cancer
Size of the tumour
Extrathyroidal extension
Complete resection?
Multifocal: yes or no
Tall cell variant: present, if yes how many cells (10% or more)?
Invasion in blood vessels and lymphatic vessels
Metastases in lymph nodes, if yes, how many are macro metastases
and how may micro metastases (micro <0.2 cm)?
in ∼5 years from now. As long as the results of such studies
are still pending, it would be prudent to refrain from a
strong position against 131I as thus far the course of the dis-
ease with 131I therapy has been so good.
Pathologists’ perspective
A critical element in the classification of PTC as low risk
is its biology. For proper decision making, it is therefore
important that the pathology results report all histological
features of the cancer associated with its biology, as well
as all information related to the Union Internationale Con-
tre le Cancer (UICC) TNM cancer staging system. This
should include the histological type of the primary tumour,
whether it is encapsulated or not, the presence or absence
of capsular and vascular invasion, and the number and
size of lymph node metastases (if lymph nodes were re-
moved). It is also important to note that the lesions for-
merly classified as the encapsulated follicular variant of
PTC have been recently reclassified as so-called noninva-
sive follicular thyroid neoplasm with papillary-like nuclear
features (NIFTP) in order to reduce overtreatment of in-
dolent lesions [28]. The presence or absence of features
associated with an adverse outcome such as tall cells, the
columnar cell variant or the hobnail variant, and lymph
or haemangio-invasion should be noted. These features
are summarised and updated in synoptic reporting systems
such as the one used by the College of American Patholo-
gists (CAP). Such a system can be readily implemented in
the Swiss situation and was recently introduced into the de-
partment of pathology of the University of Bern (see table
2).
Molecular testing of thyroid carcinomas for prediction of
patient outcome is evolving rapidly; however, to date no
single gold standard molecular marker has been identified.
BRAF mutation testing is not routinely recommended be-
cause prognostic information is controversial in many dif-
ferent studies [29–31]. BRAF mutation testing may have a
role in conjunction with molecular testing of TP53, AKT1
or PIK3CA via a targeted NGS (next generation sequenc-
ing) approach, since these double mutant PTCs are more
aggressive [32]. TERT promoter mutations, on the other
hand, can well be used as a prognostic marker – the draw-
back is that they are only found in a subset of about 7 to
8% of PTCs [33].
Discussion
The current practice of total thyroidectomy followed by ra-
dioiodine therapy in patients with DTC started a long time
before the advent of evidence-based medicine, in 1943
[34], and was used thereafter with lifesaving effects for
many patients with severe metastatic disease. The land-
mark publication by Mazzaferri and Kloos on the treatment
of patients with DTC, with 40 years of follow-up [35], was
an observational cohort study summarising data from more
than 1500 patients and describing the beneficial effect of
radioiodine therapy in patients diagnosed before availabil-
ity of computed tomography or ultrasound. Similarly, the
disputed studies that challenged the benefit of radioiodine
therapy in patients with low-risk PTC have a very compa-
rable level of evidence; they also were observational and
retrospective.
All participants agreed on the general concept of risk-
adapted treatment of patients with low-risk PTC. Many,
however, felt very uneasy with the suggested definition of
low-risk PTC in the new ATA guidelines, which did not in-
clude a size limit of the primary tumour (table 1), citing
the association between tumour size and the risk for local
and distant metastases, which showed that the risk for local
extension of PTC increased significantly when the primary
tumour exceeded 20 mm [17].
Therefore, we agreed to limit the definition of low risk to
those PTCs up to 20 mm in size, while acknowledging the
general concept for the definition of low risk as outlined by
the ATA. Thus, patients with a PTC up to 20 mm and with-
out local extension of the tumour and without macroscopic
evidence for lymph node metastases or other negative his-
tological feature (such as hobnail or tall cell cancer, vascu-
lar invasion) can be considered as having low-risk PTC.
We may have to take into account that today patients, as
well as their primary care physicians, are more informed
than some years ago and that the ATA guidelines are wide-
ly published and discussed. Therefore we may have to dis-
cuss these guidelines and explain why our recommenda-
tions differ from those proposed by the ATA.
Conclusion
– In patients with low-risk PTC below 10 mm in size that
was incidentally discovered after surgery, no further ac-
tion is required (no completion thyroidectomy if lobec-
tomy was the first surgical procedure and no radioio-
dine).
– For low-risk PTC as defined above and a size up to 20
mm a hemithyroidectomy should be the standard proce-
dure without the need for routine ipsilateral prophylac-
tic lymph node clearance and no completion thyroidec-
tomy. Routine radioiodine treatment is not
recommended. In these patients completion thyroidec-
tomy should be recommended only if histological fea-
tures representing higher aggressiveness should be seen
in the definitive histological evaluation, requiring ra-
dioiodine ablation. As an exception, for patients who
(after discussing the low but existing risk for recur-
rence) request maximal treatment another approach in-
cluding completion thyroidectomy and radioiodine
treatment can be appropriate as well.
– For patients with proven PTC on cytology and a prima-
ry tumour size of 21 to 40 mm we recommend a total
thyroidectomy followed by radioiodine treatment.
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